Shaygannejad Vahid, Ashtari Fereshteh, Alinaghian Mahsa, Norouzi Rasul, Salari Mehri, Fatehi Farzad
Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Clin Neuropharmacol. 2013 Jan-Feb;36(1):1-3. doi: 10.1097/WNF.0b013e3182764f91.
To determine the short-term safety of high-dose intravenous methylprednisolone in acute attacks of multiple sclerosis (MS).
In a prospective study, we evaluated the patients with MS who received high-dose intravenous methylprednisolone for acute attacks. By repeated physical and laboratory examinations and history taking, patients were assessed for adverse effects that would be related to pulse therapy before, within, and 3 months after the treatment.
Sixty-four patients with definite MS with acute attack were enrolled in the study in which 46 (71.9%) were female. Fifty-eight patients (90.6%) developed minor adverse effects of which the most common were palpitation, flashing, dyspepsia, insomnia, and virulent taste. On the other hand, 12 patients (18.75%) developed major adverse effects, and the most common was sinus tachycardia. Six patients (9.3%) were without any adverse effects. There was a significant relationship between the dosage of methylprednisolone (3 or 5 g) and the occurrence of major adverse effects (P = 0.025).
This study approved that high-dose intravenous methylprednisolone is a safe treatment in MS attacks and the short-term adverse effects were mostly minor and transient.
确定大剂量静脉注射甲基泼尼松龙治疗多发性硬化症（MS）急性发作的短期安全性。
在一项前瞻性研究中，我们评估了接受大剂量静脉注射甲基泼尼松龙治疗急性发作的MS患者。通过反复的体格检查、实验室检查和病史采集，在治疗前、治疗期间及治疗后3个月评估患者与冲击疗法相关的不良反应。
64例确诊为MS急性发作的患者纳入本研究，其中46例（71.9%）为女性。58例患者（90.6%）出现轻微不良反应，最常见的是心悸、闪光感、消化不良、失眠和味觉异常。另一方面，12例患者（18.75%）出现严重不良反应，最常见的是窦性心动过速。6例患者（9.3%）未出现任何不良反应。甲基泼尼松龙剂量（3或5 g）与严重不良反应的发生之间存在显著相关性（P = 0.025）。
本研究证实大剂量静脉注射甲基泼尼松龙治疗MS发作是安全的，短期不良反应大多轻微且短暂。
